274 related articles for article (PubMed ID: 27134166)
1. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
Allen E; Miéville P; Warren CM; Saghafinia S; Li L; Peng MW; Hanahan D
Cell Rep; 2016 May; 15(6):1144-60. PubMed ID: 27134166
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
3. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
4. Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.
Pisarsky L; Bill R; Fagiani E; Dimeloe S; Goosen RW; Hagmann J; Hess C; Christofori G
Cell Rep; 2016 May; 15(6):1161-74. PubMed ID: 27134168
[TBL] [Abstract][Full Text] [Related]
5. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
6. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
7. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
Franco M; Pàez-Ribes M; Cortez E; Casanovas O; Pietras K
Horm Metab Res; 2011 Nov; 43(12):884-9. PubMed ID: 21960459
[TBL] [Abstract][Full Text] [Related]
8. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
[TBL] [Abstract][Full Text] [Related]
9. Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation.
Huang C; Sheng S; Li R; Sun X; Liu J; Huang G
Oncol Rep; 2015 Feb; 33(2):875-84. PubMed ID: 25484022
[TBL] [Abstract][Full Text] [Related]
10. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
11. Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
Jiménez-Valerio G; Martínez-Lozano M; Bassani N; Vidal A; Ochoa-de-Olza M; Suárez C; García-Del-Muro X; Carles J; Viñals F; Graupera M; Indraccolo S; Casanovas O
Cell Rep; 2016 May; 15(6):1134-43. PubMed ID: 27134180
[TBL] [Abstract][Full Text] [Related]
12. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E
J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816
[TBL] [Abstract][Full Text] [Related]
13. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer.
Sutendra G; Dromparis P; Kinnaird A; Stenson TH; Haromy A; Parker JM; McMurtry MS; Michelakis ED
Oncogene; 2013 Mar; 32(13):1638-50. PubMed ID: 22614004
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
16. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.
Lee SC; Marzec M; Liu X; Wehrli S; Kantekure K; Ragunath PN; Nelson DS; Delikatny EJ; Glickson JD; Wasik MA
NMR Biomed; 2013 Jan; 26(1):106-14. PubMed ID: 22711601
[TBL] [Abstract][Full Text] [Related]
17. Periostin Limits Tumor Response to VEGFA Inhibition.
Keklikoglou I; Kadioglu E; Bissinger S; Langlois B; Bellotti A; Orend G; Ries CH; De Palma M
Cell Rep; 2018 Mar; 22(10):2530-2540. PubMed ID: 29514082
[TBL] [Abstract][Full Text] [Related]
18. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
19. Translational medicine: Cancer lessons from mice to humans.
Tuveson D; Hanahan D
Nature; 2011 Mar; 471(7338):316-7. PubMed ID: 21412332
[No Abstract] [Full Text] [Related]
20. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
